Abnormal Plasminogen Maywood I

Summary

Maywood I is a dysfunctional plasminogen. It is described in a patient (W. Y) with a reduced plasma functional activity and with a low normal antigen level. Plasminogen was isolated from the patients plasma by affinity chromatography with L-lysine-substituted Sepharose. The protein yield was 86 mg/1, which was 88% of the plasma Plg antigen level; the specific activity was 24.4 IU/mg protein compared to 28.5 IU/mg protein for the native molecule. The protein was the Glu-form determined by SDS-PAGE and by isoelectric focusing. Six major isoelectric forms were found with isoelectric points between pH's 6.40 and 5.45. Titration of the equimolar plasminogen.streptokinase complex with p-nitrophenyl-p-guanidinobenzoate gave 85% active-sites indicating a homogenous population of molecules; therefore, the propositus is a homozygote. Four different plasminogen activators: a) streptokinase, b) urokinase c) the plasmin-derived light (B) chain-streptokinase complex, and d) tissue plasminogen activator (with soluble fibrin/CNBr-fibrinogen fragments) generated little plasmin from the variant plasminogen (4.5 to 45 nM), 5% or less than that generated from normal plasminogen. At 45 nM plasminogen, the molar ratio of plasminogen : activator was 3.0 for streptokinase, 3.9 for urokinase, 7.1 for the light (B) chain-streptokinase complex, and 155 for tissue plasminogen activator. In the equimolar variant plasminogen.streptokinase complex, the active-site was slowly developed, to a maximum of 85% in 40 min; in the normal complex, 100% active-sites were developed in 15 min. The variant plasminogen forms two equimolar complexes with streptokinase (I and II), with different mobilities in PAGE, in about equal amounts. About 10% of complex I (abnormal), with a slower mobility than complex II (normal), converts to plasmin.streptokinase in 60 min, whereas about 40% of complex II converts to plasmin.streptokinase in 60 min. A kinetic defect was also found with this variant plasminogen. It showed substantially lowered kinetics of activation second-order rate constants with both streptokinase and urokinase, primarily due to lower catalytic rate constants, and with streptokinase, a higher Michaelis constant. Crossed-immunoelectrophoresis, and preparative isoelectric focusing isoelectric points did not show a charge mutation. Maywood I may be classified as a dysplasminogenemia with active center and kinetic defects, Type 1c.

• References

• 1 Aoki N. Genetic abnormalities of the fibrinolytic system. Sem Thromb Haemostas 1984; 10: 42-50
• 2 Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988; 2 Suppl 2 26-34
• 3 Robbins KC. Dysplasminogenemias. Enzyme 1988; 40: 70-8
• 4 Lijnen HR, Collen D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 1989; 3: 67-77
• 5 Robbins KC. Classification of abnormal plasminogens: Dysplasminogenemias. Thromb Haemostas 1990; 16: 217-20
• 6 Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11
• 7 Aoki N, Moroi M, Sakata Y, Yoshida N, Matsuda M. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978; 61: 1186-95
• 8 Sakata Y, Aoki N. Molecular abnormality of plasminogen. J Biol Chem 1980; 255: 5442-7
• 9 Miyata T, Iwanaga S, Sakata Y, Aoki N. Plasminogen Tochigi: Inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci USA 1982; 79: 6132-6
• 10 Miyata T, Iwanaga S, Sakata Y, Aoki N, Takamatsu J, Kamiya T. Plasminogens Tochigi II and Nagoya: Two additional molecular defects with Ala-600 to Thr replacement found in plasmin light chain variants. J Biochem (Jpn) 1984; 96: 277-87
• 11 Ichinose A, Espling ES, Takamatsu J, Saito H, Synmyozu K, Maruyama I, Martzen MR, Petersen TE, Davie EW. Characterization and diagnosis of the abnormal genes for human plasminogen. Thromb Haemostas 1989; 62: 495 (Abstract 1552)
• 12 Godwin J, Goodwin M, Brown A, Foy B, Boreisha I, Robbins KC. Successful cardiac surgery in a patient with an abnormal plasminogen, Maywood I, and recurrent thrombosis. Blood 70 Suppl 1 373 (Abstract 1348)
• 13 Robbins KC, Godwin J. Abnormal plasminogen, Maywood I. Thromb Haemostas 1989; 62: 83 (Abstract 236)
• 14 Wohl RC, Summaria L, Robbins KC. Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants. Chicago I and Chicago II. J Biol Chem 1979; 254: 9063-9
• 15 Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37° C. J Biol Chem 1980; 255: 2005-13
• 16 Wohl RC, Summaria L, Chediak J, Rosenfeld S, Robbins KC. Human plasminogen variant Chicago III. Thromb Haemostas 1982; 48: 146-52
• 17 Scharrer IM, Wohl RC, Hach V, Sinio L, Boreisha I, Robbins KC. Investigation of a congenital abnormal plasminogen, Frankfurt I, and its relationship to thrombosis. Thromb Haemostas 1986; 55: 396-401
• 18 Gaffney PJ, Curtis AD. The establishment of a standard for plasminogen (Glu-type). Thromb Haemostas 1984; 51: 376-8
• 19 Robbins KC, Summaria L, Elwyn D, Barlow GH. Further studies of the purification and characterization of human plasminogen and plasmin. J Biol Chem 1965; 240: 541-50
• 20 Summaria L, Boreisha I, Wohl RC, Robbins KC. Recombinant human Lys-plasmin and Lys-plasmin.streptokinase complex. J Biol Chem 1979; 254: 6811-4
• 21 Robbins KC, Boreisha IG. A covalent molecular weight 92000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains. Biochemistry 1987; 26: 4661-7
• 22 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 23 Lee PP, Wohl RC, Boreisha IG, Robbins KC. Kinetic analysis of covalent hybrid plasminogen activators: Effect of CNBr-degraded fibrinogen on kinetic parameters of Glu₁-plasminogen activation. Biochemistry 1988; 27: 7506-13
• 24 Becker W, Rapp W, Schwick HG, Storiko K. Methoden zur quantitativen Bestimmung von Plasmaproteinen durch Immunprôzipitation. Z Klin Chem Klin Biochem 1968; 3: 113-22
• 25 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin, and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-45
• 26 Summaria L, Arzadon L, Bernabe P, Robbins KC, Barlow GH. Characterization of the NH₂-terminal glutamic acid and NH₂-terminal lysine forms of human plasminogen isolated by affinity chromatography and isoelectric focusing methods. J Biol Chem 1973; 248: 2984-91